News

Glycyx Awarded NIH SBIR Phase 2 Grant to Advance Axelopran and Pembrolizumab Study in Head and Neck Cancer

San Francisco, CA — September 2025 – Glycyx MOR, Inc. announced today that it has been awarded a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase II grant to advance a Phase 2 clinical trial evaluating axelopran in combination with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who are taking opioids to manage cancer pain. The open-label, single-arm study will be conducted at Univers

Sep 25

BioAccess Podcast - Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics

Could opioids be silently undermining cancer immunotherapy? This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics —...

Sep 1

Bio Report Podcast - Preventing Opioids from Countering the Benefits of Cancer Immunotherapies

Many cancer patients are prescribed opioids to manage pain associated with their disease, but studies have shown that the use of these...

Aug 13

BioTechNation Podcast - Fighting Cancer, Easing Pain... Dr. Lorin Johnson, CSO, Glycyx Therapeutics

This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising...

May 8

Groundbreaking Research from UPMC Highlights Opioids’ Suppressive Impact on Immune Checkpoint Inhibitors and the Potential of Axelopran, an Opioid Antagonist to Reverse It

San Francisco, CA – December 04, 2024 – Glycyx, a clinical-stage biopharmaceutical company advancing axelopran, a novel solution to...

Dec 4, 2024